WI
REGN icon

WBI Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

WBI Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Sell
261
-936
-78% -$717K 0.06% 274
2025
Q4 		$924K Buy
1,197
+461
+63% +$313K 0.24% 124
2025
Q3 		$414K Buy
+736
New +$416K 0.11% 220

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

WBI Investments's REGN Position: Q1 2026 in Review

WBI Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 78% in Q1 2026, selling an estimated $717K and leaving 261 shares worth $202K. The position accounts for 0.06% of the portfolio, ranked #274.

WBI Investments first reported a position in REGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $924K in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • WBI Investments held 261 shares of Regeneron Pharmaceuticals worth $202K as of Q1 2026.
  • WBI Investments sold 936 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $717K.
  • Regeneron Pharmaceuticals made up 0.06% of WBI Investments's portfolio in Q1 2026, its #274 holding.
  • WBI Investments first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • WBI Investments's Regeneron Pharmaceuticals position peaked at $924K in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on WBI Investments's 13F filing for Q1 2026, filed 11 May 2026.